South Korea · Delayed Price · Currency is KRW S.Biomedics Statistics
Total Valuation
S.Biomedics has a market cap or net worth of KRW 266.28 billion. The enterprise value is 246.53 billion.
| Market Cap | 266.28B |
| Enterprise Value | 246.53B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
S.Biomedics has 12.39 million shares outstanding. The number of shares has increased by 3.58% in one year.
| Current Share Class | 12.39M |
| Shares Outstanding | 12.39M |
| Shares Change (YoY) | +3.58% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 22.35% |
| Owned by Institutions (%) | n/a |
| Float | 9.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.15 |
| PB Ratio | 6.74 |
| P/TBV Ratio | 9.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.56, with a Debt / Equity ratio of 0.51.
| Current Ratio | 6.56 |
| Quick Ratio | 6.14 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.81 |
| Interest Coverage | -7.78 |
Financial Efficiency
Return on equity (ROE) is -39.31% and return on invested capital (ROIC) is -15.05%.
| Return on Equity (ROE) | -39.31% |
| Return on Assets (ROA) | -11.94% |
| Return on Invested Capital (ROIC) | -15.05% |
| Return on Capital Employed (ROCE) | -16.69% |
| Weighted Average Cost of Capital (WACC) | 11.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.28 |
| Inventory Turnover | 3.92 |
Taxes
In the past 12 months, S.Biomedics has paid 310.17 million in taxes.
| Income Tax | 310.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.29% in the last 52 weeks. The beta is 1.47, so S.Biomedics's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | +5.29% |
| 50-Day Moving Average | 19,107.00 |
| 200-Day Moving Average | 28,424.40 |
| Relative Strength Index (RSI) | 60.28 |
| Average Volume (20 Days) | 22,764 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, S.Biomedics had revenue of KRW 16.49 billion and -12.06 billion in losses. Loss per share was -992.35.
| Revenue | 16.49B |
| Gross Profit | 8.13B |
| Operating Income | -11.28B |
| Pretax Income | -10.39B |
| Net Income | -12.06B |
| EBITDA | -8.87B |
| EBIT | -11.28B |
| Loss Per Share | -992.35 |
Balance Sheet
The company has 49.40 billion in cash and 20.18 billion in debt, with a net cash position of 29.22 billion or 2,359.41 per share.
| Cash & Cash Equivalents | 49.40B |
| Total Debt | 20.18B |
| Net Cash | 29.22B |
| Net Cash Per Share | 2,359.41 |
| Equity (Book Value) | 39.51B |
| Book Value Per Share | 2,423.15 |
| Working Capital | 46.45B |
Cash Flow
In the last 12 months, operating cash flow was -7.11 billion and capital expenditures -4.03 billion, giving a free cash flow of -11.15 billion.
| Operating Cash Flow | -7.11B |
| Capital Expenditures | -4.03B |
| Depreciation & Amortization | 2.41B |
| Net Borrowing | 20.19B |
| Free Cash Flow | -11.15B |
| FCF Per Share | -900.09 |
Margins
Gross margin is 49.27%, with operating and profit margins of -68.42% and -73.11%.
| Gross Margin | 49.27% |
| Operating Margin | -68.42% |
| Pretax Margin | -62.98% |
| Profit Margin | -73.11% |
| EBITDA Margin | -53.79% |
| EBIT Margin | -68.42% |
| FCF Margin | n/a |
Dividends & Yields
S.Biomedics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.58% |
| Shareholder Yield | -3.58% |
| Earnings Yield | -4.53% |
| FCF Yield | -4.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
S.Biomedics has an Altman Z-Score of 4.34 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.34 |
| Piotroski F-Score | 3 |